Home › Multiple Myeloma › Arizona › Tucson
Multiple Myeloma clinical trials in Tucson, AZ
4 studies for Multiple Myeloma are looking for participants at sites in and around Tucson (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RecruitingPhase 3
- Research Site, Tucson
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RecruitingPhase 3
- University of Arizona Cancer Center, Tucson
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RecruitingPhase 3
- Research Site, Tucson
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
RecruitingPhase 2
- Arizona Oncology Associates, Tucson
About Multiple Myeloma
Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. Discover symptoms, diagnostic tests, and treatments for myeloma.
More about Multiple Myeloma on MedlinePlus
Multiple Myeloma trials in other cities
- New York City, NY60 studies
- Boston, MA42 studies
- Atlanta, GA41 studies
- Houston, TX38 studies
- Durham, NC37 studies
- Nashville, TN32 studies
- Denver, CO27 studies
- Rochester, MN24 studies
- St. Louis, MO24 studies
- Columbus, OH24 studies
- Baldwin Park, CA23 studies
- Chicago, IL22 studies
Other studies in Tucson
- Breast Cancer20 studies
- Non-Small Cell Lung Cancer17 studies
- Obesity17 studies
- Overweight15 studies
- Metastatic Cancer14 studies
- Cancer (all types)12 studies
- Cardiovascular Disease12 studies
- Colorectal Cancer11 studies
- Prostate Cancer11 studies
- Steatotic Liver Disease10 studies
- Heart Failure10 studies
- High Blood Pressure10 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.